Co-stimulatory molecule CTLA-4 and the potential application in treating rheumatic diseases
- VernacularTitle:共刺激分子CTLA-4的研究进展及在风湿病治疗中的应用
- Author:
Xinping TIAN
;
Xiaofeng ZENG
- Publication Type:Journal Article
- Keywords:
CTLA-4;
CTLA-4Ig;
rheumatic disease
- From:
Basic & Clinical Medicine
2006;0(09):-
- CountryChina
- Language:Chinese
-
Abstract:
Rheumatic diseases are characterized by immunological dysfunction.T-cell medicated immune response plays a very important role in the development and persistence of rheumatic disease.CTLA-4 is an important co-stimulatory molecules expressed on T cells.It has inhibitory effect on T cell-mediated immune response.Plenty of evidences have demonstrated abnormalities in CTLA-4 alleles and proteins in patients with rheumatic diseases.Therefore,CTLA-4 has become an target in treating rheumatic diseases.CTLA-4Ig has been developed as an fusion protein which is composed of extrA-cellular domain of human CTLA-4 and the Fc fragment of human IgG1.So far,only data about CTLA-4Ig in treating rheumatoid arthritis are available.These data showed that CTLA-4Ig could relieve the symptoms of rheumatoid arthritis and retard the development of the disease.It is safe and effective.In addition,effectiveness was demonstrated even in patients who failed to response to anti-TNF monoclonal antibodies.Therefore,CTLA-4Ig is an encouraging therapy for rheumatic diseases.However,because of very short history,long-term study is needed to fully understand its role in the treatment of rheumatoid arthritis.
